Vimentin antibody (AA 1-101)
-
- Target See all Vimentin (VIM) Antibodies
- Vimentin (VIM)
-
Binding Specificity
- AA 1-101
-
Reactivity
- Human
-
Host
- Rabbit
-
Clonality
- Polyclonal
-
Conjugate
- This Vimentin antibody is un-conjugated
-
Application
- Western Blotting (WB), Immunohistochemistry (IHC), Immunofluorescence (IF)
- Sequence
- MSTRSVSSSS YRRMFGGPGT ASRPSSSRSY VTTSTRTYSL GSALRPSTSR SLYASSPGGV YATRSSAVRL RSSVPGVRLL QDSVDFSLAD AINTEFKNTR T
- Cross-Reactivity
- Human, Mouse, Rat
- Characteristics
- Polyclonal Antibodies
- Immunogen
- Recombinant fusion protein containing a sequence corresponding to amino acids 1-101 of human Vimentin (NP_003371.2).
- Isotype
- IgG
- Top Product
- Discover our top product VIM Primary Antibody
-
-
- Application Notes
- WB,1:500 - 1:2000,IHC,1:50 - 1:200,IF,1:50 - 1:200
- Comment
-
HIGH QUALITY
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Buffer
- PBS with 0.02 % sodium azide,50 % glycerol, pH 7.3.
- Preservative
- Sodium azide
- Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Storage
- -20 °C
- Storage Comment
- Store at -20°C. Avoid freeze / thaw cycles.
-
-
Direct inhibition of ACTN4 by ellagic acid limits breast cancer metastasis via regulation of β-catenin stabilization in cancer stem cells." in: Journal of experimental & clinical cancer research : CR, Vol. 36, Issue 1, pp. 172, (2018) (PubMed).
: "Network-pharmacology-based validation of TAMS/CXCL-1 as key mediator of XIAOPI formula preventing breast cancer development and metastasis." in: Scientific reports, Vol. 7, Issue 1, pp. 14513, (2017) (PubMed).
: "
-
Direct inhibition of ACTN4 by ellagic acid limits breast cancer metastasis via regulation of β-catenin stabilization in cancer stem cells." in: Journal of experimental & clinical cancer research : CR, Vol. 36, Issue 1, pp. 172, (2018) (PubMed).
-
- Target
- Vimentin (VIM)
- Alternative Name
- VIM (VIM Products)
- Synonyms
- CTRCT30 antibody, cb28 antibody, vime antibody, vim antibody, vim1 antibody, vim2 antibody, VIM antibody, Vimentin antibody, vim4 antibody, vimentin antibody, vimentin L homeolog antibody, vimentin S homeolog antibody, VIM antibody, Vim antibody, vim antibody, vim.L antibody, vim.S antibody
- Background
- This gene encodes a member of the intermediate filament family. Intermediate filamentents, along with microtubules and actin microfilaments, make up the cytoskeleton. The protein encoded by this gene is responsible for maintaining cell shape, integrity of the cytoplasm, and stabilizing cytoskeletal interactions. It is also involved in the immune response, and controls the transport of low-density lipoprotein (LDL)-derived cholesterol from a lysosome to the site of esterification. It functions as an organizer of a number of critical proteins involved in attachment, migration, and cell signaling. Mutations in this gene causes a dominant, pulverulent cataract.,CTRCT30,HEL113,Vimentin,VIM,vimentin,Cancer,Tumor biomarkers,Signal Transduction,Cell Biology & Developmental Biology,Cytoskeleton,Intermediate Filaments,Neuroscience,Cell Type Marker,Stem Cells,Neural Stem Cells,Neural Stem Cell marker,VIM
- Molecular Weight
- 53 kDa
- Gene ID
- 7431
- UniProt
- P08670
- Pathways
- Caspase Cascade in Apoptosis
-